Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells,… Read more
Remed Co.Ltd (302550) - Net Assets
Latest net assets as of September 2025: ₩39.94 Billion KRW
Based on the latest financial reports, Remed Co.Ltd (302550) has net assets worth ₩39.94 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩55.32 Billion) and total liabilities (₩15.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩39.94 Billion |
| % of Total Assets | 72.2% |
| Annual Growth Rate | 38.17% |
| 5-Year Change | 62.38% |
| 10-Year Change | N/A |
| Growth Volatility | 61.31 |
Remed Co.Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Remed Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Remed Co.Ltd (2017–2024)
The table below shows the annual net assets of Remed Co.Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩40.25 Billion | +30.70% |
| 2023-12-31 | ₩30.79 Billion | +2.93% |
| 2022-12-31 | ₩29.92 Billion | +14.64% |
| 2021-12-31 | ₩26.10 Billion | +5.29% |
| 2020-12-31 | ₩24.79 Billion | +0.66% |
| 2019-12-31 | ₩24.62 Billion | +124.98% |
| 2018-12-31 | ₩10.94 Billion | +161.50% |
| 2017-12-31 | ₩4.19 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Remed Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 350.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩9.45 Billion | 23.48% |
| Common Stock | ₩3.06 Billion | 7.61% |
| Other Components | ₩27.73 Billion | 68.91% |
| Total Equity | ₩40.25 Billion | 100.00% |
Remed Co.Ltd Competitors by Market Cap
The table below lists competitors of Remed Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mega Or
TA:MGOR
|
$43.45 Million |
|
Japan Medical Dynamic Marketing INC
F:JMD
|
$43.45 Million |
|
DANIEL THWAITES LS-25
F:7KW
|
$43.47 Million |
|
Intech Biopharm Ltd
TWO:6461
|
$43.47 Million |
|
GBM Resources Ltd
AU:GBZ
|
$43.44 Million |
|
Gunnison Copper Corp
OTCQB:GCUMF
|
$43.44 Million |
|
Prairie Operating Co.
F:7C5
|
$43.43 Million |
|
Huxen Corp
TW:2433
|
$43.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Remed Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,826,041,200 to 40,248,542,040, a change of 9,422,500,840 (30.6%).
- Net income of 7,172,078,130 contributed positively to equity growth.
- Other factors increased equity by 2,250,422,710.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩7.17 Billion | +17.82% |
| Other Changes | ₩2.25 Billion | +5.59% |
| Total Change | ₩- | 30.57% |
Book Value vs Market Value Analysis
This analysis compares Remed Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.54x to 2.42x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩2066.27 | ₩3180.00 | x |
| 2018-12-31 | ₩2118.46 | ₩3180.00 | x |
| 2019-12-31 | ₩4228.73 | ₩3180.00 | x |
| 2020-12-31 | ₩4070.80 | ₩3180.00 | x |
| 2021-12-31 | ₩4259.03 | ₩3180.00 | x |
| 2022-12-31 | ₩4882.52 | ₩3180.00 | x |
| 2023-12-31 | ₩1006.13 | ₩3180.00 | x |
| 2024-12-31 | ₩1313.68 | ₩3180.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Remed Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.82%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.07%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.47x
- Recent ROE (17.82%) is above the historical average (-2.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.87% | 0.58% | 0.50x | 3.01x | ₩-382.30 Million |
| 2018 | -67.44% | -92.21% | 0.37x | 1.97x | ₩-8.48 Billion |
| 2019 | 17.72% | 23.52% | 0.53x | 1.42x | ₩1.90 Billion |
| 2020 | -7.40% | -11.02% | 0.23x | 2.96x | ₩-4.31 Billion |
| 2021 | 2.88% | 3.73% | 0.26x | 2.96x | ₩-1.86 Billion |
| 2022 | 13.37% | 18.72% | 0.27x | 2.61x | ₩1.01 Billion |
| 2023 | 2.59% | 4.30% | 0.34x | 1.79x | ₩-2.29 Billion |
| 2024 | 17.82% | 28.07% | 0.43x | 1.47x | ₩3.15 Billion |
Industry Comparison
This section compares Remed Co.Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Remed Co.Ltd (302550) | ₩39.94 Billion | 0.87% | 0.39x | $43.44 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |